Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation: A meta-analysis of randomized controlled trials

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 4, 2013, Pages 405-415

  Han, Min ^a   Zhang, Yong ^a   Sun, Shujuan ^b   Wang, Zhongsu ^a   Wang, Jiangrong ^a   Xie, Xinxing ^a   Gao, Mei ^a   Yin, Xiangcui ^a   Hou, Yinglong ^a  

^a SHANDONG UNIVERSITY   (China)

^b Departments of Pharmacy   (China)

Author keywords

angiotensin receptor blocker; angiotensin converting enzyme inhibitor; atrial fibrillation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

DRUG EFFICACY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84886387701     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182a094a1     Document Type: Review

References (65)

1. Camm AJ, Lip GY, De Caterina R, et al; European Society of Cardiology (ESC) Committee for Practice Guidelines-CPGDocument Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413.
2. Køber L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687. (Pubitemid 351860860)
3. Oral H, Knight BP, Ozaydin M, et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol. 2002;40:100-104. (Pubitemid 34701383)
4. Themistoclakis S, Schweikert RA, Saliba WI, et al. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm. 2008;5:679-685.
5. Greiser M, Schotten U. Dynamic remodeling of intracellular Ca(2+) signaling during atrial fibrillation. J Mol Cell Cardiol. 2013;58:134-142.
6. Xu Y, Sharma D, Li G, et al. Atrial remodeling: new pathophysiological mechanism of atrial fibrillation. Med Hypotheses. 2013;80:53-56.
7. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Car-diovasc Res. 2011;89:744-753.
8. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802-809. (Pubitemid 351260071)
9. Fuchs T, Baron EL, Leitman M, et al. Does chronic atrial fibrillation induce cardiac remodeling? Echocardiography. 2013;30:140-146.
10. Tan AY, Zhou S, Ogawa M, et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008;118:916-925.
11. Iwasaki YK, Nishida K, Kato T, et al. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124:2264-2274.
12. Park HW, Shen MJ, Lin SF, et al. Neural mechanisms of atrial fibrillation. Curr Opin Cardiol. 2012;27:24-28.
13. Yu L, Scherlag BJ, Sha Y, et al. Interactions between atrial electrical remodeling and autonomic remodeling: how to break the vicious cycle. Heart Rhythm. 2012;9:804-809.
14. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13:308-328.
15. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace. 2011;13:610-625.
16. Goette A, Schön N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophy-siol. 2012;5:43-51.
17. Yamashita T, Inoue H, Okumura K, et al; J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13:473-479.
18. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007;120:85-91. (Pubitemid 47008995)
19. ACTIVE I Investigators; Yusuf S, Healey JS, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364:928-938.
20. GISSI-AF Investigators; Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360: 1606-1617.
21. Fogari R, Zoppi A, Mugellini A, et al. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mel-litus. J Cardiovasc Pharmacol. 2008;51:217-222. (Pubitemid 351450598)
22. Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008;21:1034-1039.
23. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006;27:1841-1846. (Pubitemid 44297391)
24. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther. 2012;17:34-43.
25. Galzerano D, Di Michele S, Paolisso G, et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst. 2012;13:496-503.
26. Fogari R, Zoppi A, Maffioli P, et al. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. Clin Cardiol. 2012;35:359-364.
27. Wang JG, Li Y, Shi JH, et al. Treatment of long-lasting persistent atrial fibrillation using minimally invasive surgery combined with irbesartan. Ann Thorac Surg. 2011;91:1183-1189.
28. Zhang Y, Zhang P, Mu Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2010;88:521-531.
29. Bhuriya R, Singh M, Sethi A, et al. Prevention of recurrent atrial fibrillation with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a systematic review and meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther. 2011;16:178-184.
30. Disertori M, Barlera S, Staszewsky L, et al. Systematic review and meta-analysis: renin-angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. Cardiovasc Drugs Ther. 2012;26:47-54.
31. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. (Pubitemid 26120810)
32. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available at: http://www.cochrane-hand-book.org. Accessed September 2008; Updated March 20, 2011.
33. Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol. 2009;53:24-29.
34. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1995;1:355-363.
35. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24:2090-2098.
36. Cao DJ, Mu CY, Tong F, et al. Clinical efficacy of irbesartan and amio-darone in elderly patients with paroxysmal atrial fibrillation [in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008;33:871-874.
37. Ding P, Li L, Zhang H, et al. Comparison of amiodarone plus irbesartan regimen versus amiodarone alone on maintaining sinus rhythm in rheumatic heart disease patients with persistent atrial fibrillation post valve replacement and cardioversion [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37:505-508.
38. Xie PY, Shen SH. Effect of combination of Chinese and Western medicines on sinus rhythm maintenance in patients with auricular fibrillation after conversion [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006;26:644-646.
39. Ji Q, Mei Y, Wang X, et al. Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement. Circ J. 2010;74:1873-1879.
40. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-336. (Pubitemid 34778957)
41. Madrid AH, Marín IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angio-tensin II receptor blockers. J Renin Angiotensin Aldosterone Syst. 2004;5: 114-120. (Pubitemid 39406720)
42. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47:46-50. (Pubitemid 44378223)
43. Kawamura M, Ito H, Onuki T, et al. Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. J Cardiovasc Pharmacol. 2010;55:511-517.
44. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000; 101:2612-2617. (Pubitemid 30350640)
45. Tu DN, Liao YH, Zou AR, et al. Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes. Acta Pharmacol Sin. 2008;29:913-922.
46. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512-518.
47. Iravanian S, Dudley SC Jr. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm. 2008;5:1499.
48. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:2197-2204. (Pubitemid 36724267)
49. Sheng L, Shen Q, Huang K, et al. Upregulation of b3-adrenergic receptors contributes to atrial structural remodeling in rapid pacing induced atrial fibrillation canines. Cell Physiol Biochem. 2012;30:372-381.
50. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608-2614. (Pubitemid 33104801)
51. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820. (Pubitemid 24223231)
52. Okazaki H, Minamino T, Tsukamoto O, et al. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Hypertens Res. 2006; 29:277-284. (Pubitemid 43853274)
53. Lewandowski J, Abramczyk P, Dobosiewicz A, et al. The effect of ena-lapril and telmisartan on clinical and biochemical indices of sympathetic activity in hypertensive patients. Clin Exp Hypertens. 2008;30:423-432. (Pubitemid 352009299)
54. Konno S, Hirooka Y, Kishi T, et al. Sympathoinhibitory effects of tel-misartan through the reduction of oxidative stress in the rostral ventro-lateral medulla of obesity-induced hypertensive rats. J Hypertens. 2012; 30:1992-1999.
55. Goette A, Bukowska A, Lendeckel U, et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation. 2008;117:732-742. (Pubitemid 351640674)
56. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26:2083-2092. (Pubitemid 41408600)
57. Bonilla IM, Sridhar A, Györke S, et al. Nitric oxide synthases and atrial fibrillation. Front Physiol. 2012;3:105.
58. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25:41-46. (Pubitemid 40571342)
59. Deroubaix E, Folliguet T, Rucker-Martin C, et al. Moderate and chronic hemodynamic overload of sheep atria induces reversible cellular electro-physiologic abnormalities and atrial vulnerability. J Am Coll Cardiol. 2004;44:1918-1926. (Pubitemid 39424096)
60. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359-364. (Pubitemid 35223606)
61. Tsai C, Hwang J, Shih Y, et al. Evolution of left atrial systolic and diastolic functions in different stages of hypertension: distinct effects of blood pressure control. Cardiology. 2008;109:180-187. (Pubitemid 351220519)
62. Maruyama T, Kishikawa T, Ito H, et al. Augmentation of pulmonary vein backflow velocity during left atrial contraction: a novel phenomenon responsible for progression of atrial fibrillation in hypertensive patients. Cardiology. 2008;109:33-40. (Pubitemid 350242703)
63. de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725-731.
64. Sterne JA. Investigating and dealing with publication and other biases. In: Egger M, Smith G, eds. Systematic Reviews in Health Care. London, United Kingdom: BMJ Books; 2001:189-205.
65. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-105. (Pubitemid 32681979)